P08581 (MET_HUMAN) Homo sapiens (Human)
Hepatocyte growth factor receptor UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
116 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| 107_A07 Fab in complex with fragment of the Met receptor |
Heteromer | 2×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of 2:2 c-MET/HGF holo-complex |
Heteromer P14210; | 1×SGN; | ||||
| Assess | ||||||
| Cryo-EM map of the c-MET II/HGF I/HGF II (K4 and SPH) sub-complex |
Heteromer P14210; | 1×SGN; | ||||
| Assess | ||||||
| Cryo-EM structure of the c-MET II/HGF I complex bound with HGF II in a rigid conformation |
Heteromer P14210; | 2×SGN; | ||||
| Assess | ||||||
| MET receptor in complex with InlB internalin domain and DARPin A3A |
Heteromer | |||||
| Assess | ||||||
| Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes inva… |
Heteromer P0DQD2; | |||||
| Assess | ||||||
| Cryo-EM structure of 1:1 c-MET I/HGF I complex after focused 3D refinement of holo-complex |
Heteromer P14210; | 1×SGN; | ||||
| Assess | ||||||
| Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes inva… |
Heteromer P0DQD2; | |||||
| Assess | ||||||
| Crystal structure of Onartuzumab Fab in complex with MET and HGF-beta |
Heteromer P14210; | 1×NAG; | ||||
| Assess | ||||||
| Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP2.3 |
Heteromer P14210; | |||||
| Assess | ||||||
| Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP.14 |
Heteromer P14210; | 1×NAG; 1×1PE; | ||||
| Assess | ||||||
| Crystal structure of anti-MET Fab arm of amivantamab in complex with human MET |
Heteromer | 2×NAG; 2×NAG; 1×NAG; 1×FMT; | ||||
| Assess | ||||||
| The Crystal Structure of HGF beta-chain in Complex with the Sema Domain of the Met Receptor. |
Heteromer P14210; | |||||
| Assess | ||||||
| Cryo-EM structure of 2:2 c-MET/NK1 complex |
Heteromer P14210; | |||||
| Assess | ||||||
| Crystal structure of Sema domain of the Met receptor in complex with FAB |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met |
Heteromer P22681; | |||||
| Assess | ||||||
| DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX |
Heteromer P62993; | |||||
| Assess | ||||||
| Crystal structure of the c-Met kinase domain in complex with a pyrazolone inhibitor | homo-2-mer | 2×75H; | ||||
| Assess | ||||||
| Structure of c-Met with pyrimidone inhibitor 50 | homo-2-mer | 2×MT4; | ||||
| Assess | ||||||
| Structure of c-Met with pyrimidone inhibitor 7 | homo-2-mer | 2×MT3; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN C… | homo-2-mer | 2×5B4; | ||||
| Assess | ||||||
| MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody | monomer | 1×84M; 1×GOL; 1×CL; | ||||
| Assess | ||||||
| MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody | monomer | 1×84S; 1×CL; | ||||
| Assess | ||||||
| MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody | monomer | 1×84P; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of human c-Met kinase domain with its inhibitor | monomer | 1×DF6; 1×CL; | ||||
| Assess | ||||||
| Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523 | monomer | 1×CL; 1×SX8; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET | monomer | |||||
| Assess | ||||||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in c… | monomer | 1×KSA; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in c… | monomer | 1×CKK; | ||||
| Assess | ||||||
| Structure of MET receptor tyrosine kinase in complex with ATP | monomer | 1×MG; 1×CL; 1×ATP; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in c… | monomer | 1×320; | ||||
| Assess | ||||||
| c-Met Kinase in Complex with NVP-BVU972 | monomer | 1×3QT; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in c… | monomer | 1×319; | ||||
| Assess | ||||||
| Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523 | monomer | 1×CL; 1×SX8; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in c… | monomer | 1×L8V; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in c… | monomer | 1×1FN; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in c… | monomer | 1×353; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with LY2801653 | monomer | 1×L1X; | ||||
| Assess | ||||||
| Structure of the apo MET receptor kinase in the dually-phosphorylated, activated state | monomer | |||||
| Assess | ||||||
| Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-8033 analog | monomer | 1×1JC; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with pyrazolone inhibitor 26 | monomer | 1×03X; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with pyrazolone inhibitor 58a | monomer | 1×044; | ||||
| Assess | ||||||
| Structural Characterization of autoinhibited c-Met kinase | monomer | |||||
| Assess | ||||||
| Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-2461 analog | monomer | 1×M61; | ||||
| Assess | ||||||
| Structure of dually-phosphorylated MET receptor kinase in complex with an MK-2461 analog with speci… | monomer | 1×Q6W; | ||||
| Assess | ||||||
| Crystal structure of c-Met mutant Y1230H in complex with compound 14 | monomer | 1×CL; 1×62E; | ||||
| Assess | ||||||
| Human c-Met Kinase in complex with quinoxaline inhibitor | monomer | 1×IHX; 3×GBL; | ||||
| Assess | ||||||
| Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197 | monomer | 1×M97; | ||||
| Assess | ||||||
| c-MET Y1234E,Y1235E mutant in complex with Tepotinib | monomer | 1×3E8; | ||||
| Assess | ||||||
| human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitor | monomer | 1×CL; 2×IPA; 1×DFQ; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with AMG 337 | monomer | 1×5T1; | ||||
| Assess | ||||||
| Crystal structure of D1228V c-MET bound by compound 10 | monomer | 1×W3W; | ||||
| Assess | ||||||
| Crystal structure of CMET in complex with novel inhibitor | monomer | 1×DWF; | ||||
| Assess | ||||||
| Crystal structure of c-Met kinase domain in complex with LXM108 | monomer | 1×66L; | ||||
| Assess | ||||||
| Crystal structure of D1228V cMET bound by foretinib | monomer | 1×88Z; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)et… | monomer | 1×46G; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)e… | monomer | 1×44X; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with triazolopyridazine inhibitor 2 | monomer | 1×0JJ; | ||||
| Assess | ||||||
| Crystal structure of c-Met with triazolopyridazine inhibitor 13 | monomer | 1×B2D; | ||||
| Assess | ||||||
| Crystal structure of D1228V c-MET bound by compound 1. | monomer | 1×GOL; 1×MDI; | ||||
| Assess | ||||||
| x-ray structure of c-Met with inhibitor. | monomer | 1×AM7; | ||||
| Assess | ||||||
| X-ray Structure of c-Met kinase in complex with inhibitor (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)e… | monomer | 1×5TF; | ||||
| Assess | ||||||
| Crystal structure of CMET in complex with a novel inhibitor | monomer | 1×5IE; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF CMET WT with compound 3 | monomer | 1×63B; | ||||
| Assess | ||||||
| Crystal structure of D1228V c-MET bound by compound 15 | monomer | 1×W3R; | ||||
| Assess | ||||||
| Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,… | monomer | 1×F47; | ||||
| Assess | ||||||
| X-ray Structure of PF-04217903 bound to the kinase domain of c-Met | monomer | 1×KRW; | ||||
| Assess | ||||||
| Crystal structure of CMET in complex with a novel inhibitor | monomer | 1×5I9; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD. | monomer | 1×63K; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with triazolopyridinone inhibitor 3 | monomer | 1×0JK; | ||||
| Assess | ||||||
| X-ray Structure of PF-02341066 bound to the kinase domain of c-Met | monomer | 1×VGH; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with triazolopyridinone inhibitor 24 | monomer | 1×0JL; | ||||
| Assess | ||||||
| X-ray Structure of c-Met kinase in complex with inhibitor (S)-6-(1-(6- (1-methyl-1H-pyrazol-4-yl)-(… | monomer | 1×W9Z; | ||||
| Assess | ||||||
| Crystal structure of c-Met in complex with naphthyridinone inhibitor 5 | monomer | 1×5SZ; | ||||
| Assess | ||||||
| Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)meth… | monomer | 1×4K0; | ||||
| Assess | ||||||
| X-ray Structure of c-Met with triazolopyridazine Inhibitor. | monomer | 1×L5G; | ||||
| Assess | ||||||
| Structure of the kinase domain of c-Met bound to XL880 (GSK1363089) | monomer | 1×88Z; | ||||
| Assess | ||||||
| Crystal structure of c-Met-M1250T in complex with SAR125844. | monomer | 1×63K; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 6 | monomer | 1×SWN; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound S1 | monomer | 1×SVT; 2×DMS; 4×SO4; | ||||
| Assess | ||||||
| X-ray structure of c-Met with triazolopyridazine inhibitor. | monomer | 1×LKG; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 7 | monomer | 1×SWK; | ||||
| Assess | ||||||
| Human c-Met Kinase in complex with azaindole inhibitor | monomer | 1×ZZY; 2×GBL; | ||||
| Assess | ||||||
| Crystal structure of c-Met L1195V in complex with SAR125844 | monomer | 1×63K; | ||||
| Assess | ||||||
| Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors | monomer | 1×3E8; 3×GBL; | ||||
| Assess | ||||||
| Crystal structure of CMET in complex with novel inhibitor | monomer | 1×5QQ; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 1 | monomer | 1×SV5; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 8 | monomer | 1×SW8; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 5 | monomer | 1×DMS; 1×SV8; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 9 | monomer | 1×SW5; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITOR | monomer | 1×6TD; | ||||
| Assess | ||||||
| Crystal structure of D1228V c-MET bound by compound 29 | monomer | 1×GOL; 1×EDO; 1×FMT; 1×W49; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 3 | monomer | 1×SWB; | ||||
| Assess | ||||||
| Crystal structure of wild-type c-MET bound by compound 2 | monomer | 1×W40; | ||||
| Assess | ||||||
| Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-dihy… | monomer | 1×6XP; | ||||
| Assess | ||||||
| X-ray Structure of PHA-00665752 bound to the kinase domain of c-Met | monomer | 1×PFY; | ||||
| Assess | ||||||
| X-ray Structure of c-Met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo(4… | monomer | 1×6XE; | ||||
| Assess | ||||||
| Crystal structure of D1228V c-MET bound by compound 16 | monomer | 10×IOD; 1×W3N; | ||||
| Assess | ||||||
| Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor | monomer | 1×3EH; 2×7PE; | ||||
| Assess | ||||||
| Crystal structure of D1228V c-MET bound by compound 2 | monomer | 1×W40; | ||||
| Assess | ||||||
| Crystal structure of cMET kinase domain bound by D6808 | monomer | 1×KGL; | ||||
| Assess | ||||||
| Crystal structure of cMET kinase domain bound by compound 9Y | monomer | 1×I94; | ||||
| Assess | ||||||
| Crystal structure of wild-type cMET bound by foretinib | monomer | 1×CL; 1×88Z; | ||||
| Assess | ||||||
| Crystal structure of D1228V cMET bound by BMS-777607 | monomer | 1×353; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of cMET kinase domain bound by compound 9I | monomer | 1×I90; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 2 | monomer | 1×SVK; 1×CL; 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of cMET in complex with novel inhibitor | monomer | 1×0J8; | ||||
| Assess | ||||||
| C-Met in complex with OSI ligand | monomer | 1×1RU; 2×GBL; | ||||
| Assess | ||||||
| Crystal structure of CMET in complex with novel inhibitor | monomer | 1×0J3; | ||||
| Assess | ||||||
| c-MET Y1235D mutant in complex with Tepotinib | monomer | 1×3E8; | ||||
| Assess | ||||||
| X-ray structure of SU11274 bound to c-Met | monomer | 1×AM8; | ||||
| Assess | ||||||
| c-MET F1200I mutant in complex with Tepotinib | monomer | 1×3E8; 3×EDO; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of wild-type cMET bound by savolitinib | monomer | 1×V0L; | ||||
| Assess | ||||||
| Crystal structure of c-MET bound by compound 4 | monomer | 1×EDO; 1×SVH; | ||||
| Assess | ||||||
| Crystal structure of wild-type c-MET bound by compound 7. | monomer | 4×SO4; 1×MDI; | ||||
| Assess | ||||||
| Solution structure of the PSI domain from the Met receptor | monomer | |||||
| Assess | ||||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6gcu.1.A | monomer | 0.79 | 100.00 | |||
| Assess | ||||||
| 7mo7.1.D | monomer | 0.76 | 100.00 | |||
| Assess | ||||||
| 6jrx.1.A | monomer | 0.68 | 37.97 | |||
| Assess | ||||||
6 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 6gcu.1.A | monomer | 0.79 | 100.00 | ||
| Assess | ||||||
| Isoform 2 | 7mo7.1.D | monomer | 0.76 | 100.00 | ||
| Assess | ||||||
| Isoform 2 | 2uzy.1.B | monomer | 0.73 | 99.72 | ||
| Assess | ||||||
| Isoform 2 | 8a2d.1.A | monomer | 0.68 | 37.69 | ||
| Assess | ||||||
| Isoform 3 | 6gcu.1.A | monomer | 0.80 | 100.00 | ||
| Assess | ||||||
| Isoform 3 | 7mo7.1.B | monomer | 0.76 | 98.95 | ||
| Assess | ||||||